These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 34296279)
1. Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics. Akimov SS; Jiang M; Kedaigle AJ; Arbez N; Marque LO; Eddings CR; Ranum PT; Whelan E; Tang A; Wang R; DeVine LR; Talbot CC; Cole RN; Ratovitski T; Davidson BL; Fraenkel E; Ross CA Hum Mol Genet; 2021 Nov; 30(24):2469-2487. PubMed ID: 34296279 [TBL] [Abstract][Full Text] [Related]
2. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H Mol Brain; 2012 May; 5():17. PubMed ID: 22613578 [TBL] [Abstract][Full Text] [Related]
3. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310 [TBL] [Abstract][Full Text] [Related]
4. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. HD iPSC Consortium Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968 [TBL] [Abstract][Full Text] [Related]
5. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons. Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602 [TBL] [Abstract][Full Text] [Related]
9. Epigenetic and transcriptional modulation of WDR5, a chromatin remodeling protein, in Huntington's disease human induced pluripotent stem cell (hiPSC) model. Baronchelli S; La Spada A; Ntai A; Barbieri A; Conforti P; Jotti GS; Redaelli S; Bentivegna A; De Blasio P; Biunno I Mol Cell Neurosci; 2017 Jul; 82():46-57. PubMed ID: 28476540 [TBL] [Abstract][Full Text] [Related]
10. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells. Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411 [TBL] [Abstract][Full Text] [Related]
11. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys. Cho IK; Yang B; Forest C; Qian L; Chan AWS PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183 [TBL] [Abstract][Full Text] [Related]
12. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Camnasio S; Delli Carri A; Lombardo A; Grad I; Mariotti C; Castucci A; Rozell B; Lo Riso P; Castiglioni V; Zuccato C; Rochon C; Takashima Y; Diaferia G; Biunno I; Gellera C; Jaconi M; Smith A; Hovatta O; Naldini L; Di Donato S; Feki A; Cattaneo E Neurobiol Dis; 2012 Apr; 46(1):41-51. PubMed ID: 22405424 [TBL] [Abstract][Full Text] [Related]
13. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Jeon I; Lee N; Li JY; Park IH; Park KS; Moon J; Shim SH; Choi C; Chang DJ; Kwon J; Oh SH; Shin DA; Kim HS; Do JT; Lee DR; Kim M; Kang KS; Daley GQ; Brundin P; Song J Stem Cells; 2012 Sep; 30(9):2054-62. PubMed ID: 22628015 [TBL] [Abstract][Full Text] [Related]
14. Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway. Castiglioni V; Onorati M; Rochon C; Cattaneo E Neurobiol Dis; 2012 Apr; 46(1):30-40. PubMed ID: 22227000 [TBL] [Abstract][Full Text] [Related]
15. Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy. Csobonyeiova M; Polak S; Danisovic L Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32213859 [TBL] [Abstract][Full Text] [Related]
17. iPSC-based drug screening for Huntington's disease. Zhang N; Bailus BJ; Ring KL; Ellerby LM Brain Res; 2016 May; 1638(Pt A):42-56. PubMed ID: 26428226 [TBL] [Abstract][Full Text] [Related]
18. Construction of human 3D striato-nigral assembloids to recapitulate medium spiny neuronal projection defects in Huntington's disease. Wu S; Hong Y; Chu C; Gan Y; Li X; Tao M; Wang D; Hu H; Zheng Z; Zhu Q; Han X; Zhu W; Xu M; Dong Y; Liu Y; Guo X Proc Natl Acad Sci U S A; 2024 May; 121(22):e2316176121. PubMed ID: 38771878 [TBL] [Abstract][Full Text] [Related]
19. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells. Xu X; Tay Y; Sim B; Yoon SI; Huang Y; Ooi J; Utami KH; Ziaei A; Ng B; Radulescu C; Low D; Ng AYJ; Loh M; Venkatesh B; Ginhoux F; Augustine GJ; Pouladi MA Stem Cell Reports; 2017 Mar; 8(3):619-633. PubMed ID: 28238795 [TBL] [Abstract][Full Text] [Related]